CHMP recommends approval of 2 drug offers for Perivane's Squibb Opdivo
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Recently, BMS announced that the EuropeanMedicines(http://Administration (EMA) humanproducts formedicine (http://products(http://Committee (CHMP) recommended the approval of Opdivo (Odivo, nivolab, Navuriu umono) two drug treatment options for patients with lymph nodes or metastatic melanoma after surgeryThe specific dose is:(1) every 2 weeks (Q2W) 240 mg dose infusion of more than 30 minutes of medication,(2) every 4 weeks (Q4W) 480 mg dose infusion 60 minutes or more drug regimenCHMP's comments will now be submitted to the European Commission (EC) and a final review decision is expected in about two monthsAbout Opdivo
Opdivo is a PD-1/PD-L1 immunotherapy designed to use the body's own immune system to fight cancer and kill cancer cells by blocking the PD-1/PD-L1 signaling pathway, and Opdivo has the potential to treat a variety of types of tumors Opdivo was approved in July 2014 To date, Opdivo has been approved by more than 60 countries around the world as an important treatment option for a wide range of cancers In October 2015, Opdivo-Yervoy immunocombination therapy was approved as the first joint immuno-oncology treatment for metastatic melanoma, which has been approved in more than 50 countries around the world
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
